MAP2K7 and neurofibromatosis type 1: Mirdametinib blocks MEK phosphorylation and downstream ERK signaling, resulting in reduced tumor growth and symptom burden in NF1 patients.99 The drug is orally bioavailable and is suitable for use in both adult and pediatric populations.